32H March/April 2021 Tablets & Capsules
ers have been investing in vitamins
and multivitamin products because
of their immune support functions,
which will also drive market growth.
The report identifies Amway, Herb-
alife Nutrition, ADM, Pfizer, Abbott
Laboratories. Arkopharma Laborato-
ries, Bayer, Glanbia, Nature's Sunshine
Products, FANCL, Danisco, Bionova
Lifesciences, XanGo, Ekomir, Ameri-
can Health, Pure Encapsulations, UST
Manufacturing, Capstone Nutrition,
Anona, and Plantafood Medical as key
market players.
number of participants, substantial
differences in the health status of the
participant groups, and the assump-
tion that essential nutrients behave
like pharmaceuticals. The statement
goes on to say that the study and com-
mentary make broad generalizations
and that healthcare practitioners and
consumers should approach the study
results with skepticism. To read the
full statement, visit www.crnusa.org.
Dietary supplements market to be
valued at $204.7 billion by 2026
DUBLIN, Ireland—The global
dietary supplements market is pro-
jected to reach $204.7 billion by 2026,
growing at a compound annual rate of
7 percent during the forecast period,
according to a report from Research
and Markets. Major factors driving
market growth include the increasing
prevalence of chronic diseases and
growing consumer awareness about
the health benefits of on-the-go sup-
plements. Additionally, due to the
pandemic, supplement manufactur-
CRN points out flaws
of JAMA study
WA S H I N G T O N , D C —T h e
dietary supplement and functional
food trade association Council for
Responsible Nutrition (CR N) has
released a statement by its president
and chief executive officer, Steve
Mister, dismissing a recent study's con-
clusions about the effects of vitamin
C and zinc on Covid-19. The study,
titled " Effect of High-Dose Zinc
and Ascorbic Acid Supplementation
vs Usual Care on Symptom Length
and Reduction Among Ambulatory
Patients With SARS-CoV-2 Infection"
and an accompanying commentary
were published online in the Journal of
the American Medical Association (JAMA)
Open Network. Mister's statement says
the study and the commentary do
not provide insight on the role of
nutrients in reducing Covid-19 risks
or how to treat the disease. The state-
ment argues that the study suffered
from several issues including a weak,
open-label trial design, an insufficient
with our Co-Processed
Multifunctional Excipients
Simplify Labels
and Enhance
Compressibility
Download From
INNOPHOS.COM
NEW WHITEPAPER!
